Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI More Accurate than Sonographers in Assessing and Diagnosing Cardiac Function

By HospiMedica International staff writers
Posted on 03 Sep 2022

Accurate assessment of left ventricular ejection fraction (LVEF) is essential for diagnosing cardiovascular disease and making treatment decisions. More...

However, human assessment is often based on a small number of cardiac cycles that can result in high inter-observer variability. Now, a new study has found that preliminary assessment by artificial intelligence (AI) is superior to initial sonographer assessment in patients undergoing echocardiographic evaluation of cardiac function.

EchoNet-Dynamic is a deep learning algorithm that was trained on echocardiogram videos to assess cardiac function and was previously shown to assess LVEF with a mean absolute error of 4.1-6.0%. The algorithm uses information across multiple cardiac cycles to minimize error and produce consistent results. Researchers at the Smidt Heart Institute at Cedars-Sinai (Los Angeles, CA, USA) tested whether AI or sonographer assessment of LVEF is more frequently adjusted by a reviewing cardiologist. The standard clinical workflow for determining LVEF by echocardiography is that a sonographer scans the patient; the sonographer provides an initial assessment of LVEF; and then a cardiologist reviews the assessment to provide a final report of LVEF. In this clinical trial, the sonographer’s scan was randomly allocated 1:1 to AI initial assessment or sonographer initial assessment, after which blinded cardiologists reviewed the assessment and provided a final report of LVEF.

The researchers compared how much cardiologists changed the initial assessment by AI to how much they changed the initial assessment by sonographer. The primary endpoint was the frequency of a greater than 5% change in LVEF between the initial assessment (AI or sonographer) and the final cardiologist report. The trial was designed to test for non-inferiority, with a secondary objective of testing for superiority. The study included 3,495 transthoracic echocardiograms performed on adults for any clinical indication. The proportion of studies substantially changed was 16.8% in the AI group and 27.2% in the sonographer group (difference -10.4%, 95% confidence interval [CI] -13.2% to -7.7%, p<0.001 for non-inferiority, p<0.001 for superiority). The safety endpoint was the difference between the final cardiologist report and a historical cardiologist report. The mean absolute difference was 6.29% in the AI group and 7.23% in the sonographer group (difference -0.96%, 95% CI -1.34% to -0.54%, p<0.001 for superiority).

“There has been much excitement about the use of AI in medicine, but the technologies are rarely assessed in prospective clinical trials,” said Dr. David Ouyang of the Smidt Heart Institute at Cedars-Sinai. “We previously developed one of the first AI technologies to assess cardiac function (left ventricular ejection fraction; LVEF) in echocardiograms and in this blinded, randomized trial, we compared it head to head with sonographer tracings. This trial was powered to show non-inferiority of the AI compared to sonographer tracings, and so we were pleasantly surprised when the results actually showed superiority with respect to the pre-specified outcomes.”

“We learned a lot from running a randomized trial of an AI algorithm, which hasn’t been done before in cardiology,” added Dr. Ouyang. “First, we learned that this type of trial is highly feasible in the right setting, where the AI algorithm can be integrated into the usual clinical workflow in a blinded fashion. Second, we learned that blinding really can work well in this situation. We asked our cardiologist over-readers to guess if they thought the tracing they had just reviewed was performed by AI or by a sonographer, and it turns out that they couldn’t tell the difference – which both speaks to the strong performance of the AI algorithm as well as the seamless integration into clinical software. We believe these are all good signs for future trial research in the field.”

“We are excited by the implications of the trial. What this means for the future is that certain AI algorithms, if developed and integrated in the right way, could be very effective at not only improving the quality of echo reading output but also increasing efficiencies in time and effort spent by sonographers and cardiologists by simplifying otherwise tedious but important tasks,” concluded Dr. Ouyang. “Embedding AI into clinical workflows could potentially provide more precise and consistent evaluations, thereby enabling earlier detection of clinical deterioration or response to treatment.”

Related Links:
Cedars-Sinai 


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.